User:Johnfravolda
class="wikitable sortable"
!Drug Name!!Maker!!Disease Category!!Purpose!!2006!!2009!!DrugBank | ||||||
ABT-263 | Abbott | Cancer | Lymphoma, etc. | ? | [http://www.clinicaltrials.gov/ct2/results?term=ABT-263 PI] | 0 |
ABT-333 | Abbott | Infectious, virus | HCV | ? | [http://www.clinicaltrials.gov/ct2/results?term=ABT-333 PI] | 0 |
ABT-143 | Abbott | Cardiovascular | Cholesterol, a statin drug | ? | [http://www.clinicaltrials.gov/ct2/results?term=ABT-143 PIII] | 0 |
ABT-335 | Abbott | Cardiovascular | Cholesterol, a statin drug | ? | [http://www.clinicaltrials.gov/ct2/results?term=ABT-335 PIII] | 0 |
ABT-510 (Thrombospondin Analogue) | Abbott | Cancer | Head, neck | ? | [http://www.clinicaltrials.gov/ct2/results?term=ABT-510 PII] | 0 |
ABT-751 | Abbott | Cancer | non-small cell lung | ? | [http://www.clinicaltrials.gov/ct2/results?term=ABT-751 PI-PII some studies terminated] | 0 |
ABT-894 | Abbott | Diabetes | Diabetic Neuropathies | ? | [http://www.clinicaltrials.gov/ct2/results?term=ABT-894 PII] | 0 |
ABT-450 | Abbott | Infectious, virus | HCV | ? | [http://www.clinicaltrials.gov/ct2/results?term=ABT-450 PI] | 0 |
ABT-874 | Abbott | Autoimmune | Psoriasis | ? | [http://www.clinicaltrials.gov/ct2/results?term=ABT-874 PIII] | |
ABT-888 | Abbott | Cancer | Leukimia, Chronic Myeloproliferative Disorders | ? | [http://www.clinicaltrials.gov/ct2/results?term=ABT-888 PI, PII] | 0 |
ABT-869 | Abbott | Cancer | Solid tumor, advanced, metastatic | ? | [http://www.clinicaltrials.gov/ct2/results?term=ABT-869 PI PII] | 0 |
ABT-102 | Abbott | ? | ? | ? | [http://www.clinicaltrials.gov/ct2/results?term=ABT-102 PI] | 0 |
ABT-089 | Abbott | Neurological | ADHD | ? | [http://www.clinicaltrials.gov/ct2/results?term=ABT-089 PII some terminated] | 0 |
ABT-126 | Abbott | Neurological | Alzheimer's disease | ? | [http://www.clinicaltrials.gov/ct2/results?term=ABT-126 PI] | 0 |
ABT-072 | Abbott | Infectious, virus | HCV | ? | [http://www.clinicaltrials.gov/ct2/results?term=ABT-072 PI] | 0 |
Cetrorelix Pamoate | AEterna Zentaris | Prostate | Benign prostatic hyperplasia | ? | [http://www.clinicaltrials.gov/ct2/results?term=Cetrorelix+Pamoate PIII] | 0 |
CPI-300 | IntelGenx and Cary Pharmaceuticals | Neurological | antidepressant | ? | ? | 0 |
Tigecycline (Tygacil) | Wyeth | Infectious, Antibiotic | MRSA | [http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21-821_Tygacil.cfm approved] | [http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21-821_Tygacil.cfm approved] | 00560[http://www.drugbank.ca/drugs/DB00560 DB] |
Mecasermin (Increlex) | Tercia | Hormone | Growth factor, synthetic IGF-1 | [http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021839_IncrelexTOC.cfm approved] | [http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021839_IncrelexTOC.cfm approved] | 01277[http://www.drugbank.ca/drugs/DB01277 DB] |
Dalbavancin (Zeven) | Pfizer | Infectious, Antibiotic | Gram+ (MRSA, MRSE) | Awaiting regulatory decision | [http://www.clinicaltrials.gov/ct2/results?term=dalbavancin PIII active] | 0 |
Denosumab (AMG 162) | Amgen | Osteoporosis | Treats osteoporosis | Late-stage trial | [http://www.clinicaltrials.gov/ct2/results?term=denosumab PIII active] | 0 |
Dimebolin, (Dimebon) | Medivation | Neurological | Alzheimer's disease | ? | [http://www.clinicaltrials.gov/ct2/results?term=Dimebon PI PII] | 0 |
Gardasil | Merck | Infectious, virus | Vaccine prevents hpv/cervical cancer | Late-stage trial | [http://www.fda.gov/cber/products/gardasil.htm approved] | 0 |
Ranibizumab (Lucentis) | Genentech, Novartis | Vision | Treats macular degeneration | Late-stage trial | [http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/125156s0000_LucentisTOC.cfm approved] | 01270[http://www.drugbank.ca/drugs/DB01270 DB] |
Belimumab (Benlysta or LymphoStat-B) | Human Genome Sciences, GlaxoSmithKline | Autoimmune | Treats lupus, rheumatoid arthritis | Mid-stage trial | [http://www.clinicaltrials.gov/ct2/results?term=Belimumab PII active] | 0 |
Maraviroc | Pfizer | Infectious, virus | Treats HIV/AIDS | Late-stage trial | [http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022128_selzentry_toc.cfm approved] | 04835[http://www.drugbank.ca/drugs/DB04835 DB] |
Aflibercept (AVE005, VEGF-trap) | Regeneron | Cancer | Ovarian cancer | ? | [http://www.clinicaltrials.gov/ct2/results?term=aflibercept PII PIII] | 0 |
Stamulumab (MYO-029) | Wyeth | Muscular dystrophy | Treats muscular dystrophy | Early-stage clinical trial | [http://www.clinicaltrials.gov/ct2/results?term=Stamulumab PII] | 0 |
Ciliary Neurotrophic Factor implant (NT-501) | Neurotech USA | Vision | RP, AMD, source of CNTF | ?? | [http://www.clinicaltrials.gov/ct2/results?term=NT-501 PIII active] | 0 |
VEGF structural antagonist implant (NT-503) | Neurotech USA | Vision | wet AMD, source of VEGF antagonist | ?? | ?? | 0 |
Disufenton sodium (NXY-059) | Renovis, AstraZeneca | Neurological | Stroke | Late-stage trial | [http://www.clinicaltrials.gov/ct2/results?term=Disufenton+sodium PIII completed] | 0 |
Varenicline (Champix) | Pfizer | Neurological | Smoking addiction | Late-stage trial | approved | 01273[http://www.drugbank.ca/drugs/DB01273 DB] |
Tarenflurbil (Flurizan) | Myriad Genetics | Neurological | Alzheimer's disease | Late-stage trial | [http://www.forbes.com/feeds/ap/2009/05/04/ap6375777.html abandoned] | 0 |
Gaboxadol | Merck, Lundbeck | Neurological | Sleeplessness | Late-stage trial | [http://www.fiercebiotech.com/story/merck-lundbeck-end-gaboxadol-development/2007-03-28 abandoned] | 0 |
Indiplon | Neurocrine Biosciences, Pfizer | Neurological | Sleeplessness | Late-stage trial | [http://www.clinicaltrials.gov/ct2/results?term=Indiplon abandoned?] | 0 |
Natalizumab(Tysabri, Antegren) | Biogen Idec, Elan | Neurological | Multiple sclerosis | FDA-approved but withdrawn | In use under observation | 00108[http://www.drugbank.ca/drugs/DB00108 DB] |
Ruboxistaurin (Arxxant) | Eli Lilly | Diabetes | Treat complications | Late-stage trial | [http://www.clinicaltrials.gov/ct2/results?term=Ruboxistaurin PIII active] | 0 |
Tesaglitazar (Galida) | AstraZeneca | Diabetes | Lower blood sugar and cholesterol | Late-stage trial | [http://diabetes.taragana.net/diabetes-drug-galida-2-dropped-by-astrazeneca-plcs-aznl/ abandoned] | 0 |
Vildagliptin (Galvus) | Novartis | Diabetes | Control blood sugar | Late-stage trial | abandoned 2008 | 0 |
Sitagliptin (Januvia, MK-0431) | Merck | Diabetes | Control blood sugar | Late-stage trial | approved | 01261[http://www.drugbank.ca/drugs/DB01261 DB] |
Darapladib (480848 ) | GlaxoSmithKline | Cardiovascular | Prevent atherosclerosis and heart attack | Late-stage trial | Darapladib | 0 |
Rimonabant (Acomplia) | Sanofi-Synthelabo | Cardiovascular | Combat obesity; reduce risk of heart disease | Awaiting regulatory decision | approved | 06155[http://www.drugbank.ca/drugs/DB06155 DB] |
AGI-1067 | AtheroGenics | Cardiovascular | Combat artery inflammation | Late-stage trial | [http://seekingalpha.com/article/33118-astrazeneca-terminates-production-of-atherogenics-agi-1067-beats-pretax-estimates abandoned] | 0 |
Alfimeprase | Nuvelo | Cardiovascular | Clot-buster | Late-stage trial | [http://www.drugresearcher.com/Emerging-targets/Three-strikes-for-Bayer-as-alfimeprase-trials-fail abandoned] | 0 |
Celacade | Vasogen | Cardiovascular | Treat heart failure | Late-stage trial | Celacade | 0 |
Veliflapon (DG031) | DeCode Genetics | Cardiovascular | Combat artery inflammation | Mid-stage trial | [http://www.clinicaltrials.gov/ct2/results?term=Veliflapon PIII suspended ??deCODE in bankruptcy] | 0 |
ETC-216 | Pfizer, Esperion Therapeutics | Cardiovascular | Remove cholesterol from arteries | Mid-stage trial | [http://www.drugdevelopment-technology.com/projects/etc/ ??] [http://www.esperion.com/products-research/product-candidates.php ETC-216 absent] | 0 |
ETC-1002 | Pfizer, Esperion Therapeutics | Cardiovascular | inhibit fatty acid synthesis, promote fatty acid degredation | ?? | [http://www.esperion.com/products-research/product-candidates.php Candidates] | 0 |
Lipitor-torcetrapib | Pfizer | Cardiovascular | Raise good cholesterol | Late-stage trial | Torcetrapib [http://pipeline.corante.com/archives/2006/12/03/the_torcetrapib_catastrophe.php abandoned] | 0 |
CP-690,550 ( JAK-3 inhibitor) | Pfizer | Autoimmune | Rheumatoid Arthritis | ? | [http://www.clinicaltrials.gov/ct2/results?term=CP-690%2C550 PIII] | |
LY518674 (PPAR alpha agonist) | Eli Lilly, Ligand Pharmaceuticals | Cardiovascular | Raise good cholesterol, lower triglycerides | Mid-stage trial | [http://www.medscape.com/viewarticle/554105 ??] | 0 |
Aliskiren (Rasilez) | Novartis | Cardiovascular | Reduce high blood pressure | Late-stage trial | approved | 01258[http://www.drugbank.ca/drugs/DB01258 DB] |
Sitaxentan (Thelin) | Pfizer, Encysive Pharmaceuticals | Cardiovascular | Treat pulmonary hypertension | Awaiting regulatory decision | 0 [http://www.reuters.com/article/pressRelease/idUS49297+14-Jan-2008+PNW20080114 approved outside US] [http://www.drugs.com/nda/thelin_070906.html FDA letter] | 0 |
Acapodene | GTx | Cancer | Prostate cancer prevention | Late-stage trial | approved | 00539[http://www.drugbank.ca/drugs/DB00539 DB] |
Ridaforolimus (AP23573) | Ariad Pharmaceuticals | Cancer | Sarcoma | Mid-stage trial | [http://www.clinicaltrials.gov/ct2/results?term=ridaforolimus recruiting PIII] | 0 |
Abatacept (Orencia) | Bristol-Myers Squibb | Autoimmune | Rheumatoid arthritis | ? | [http://www.clinicaltrials.gov/ct2/results?term=abatacept PIII] | 0 |
Dasatinib | Bristol-Myers Squibb | Cancer | Leukemia | Awaiting regulatory decision | approved | 01254[http://www.drugbank.ca/drugs/DB01254 DB] |
Ipilimumab | Medarex, Bristol-Myers Squibb | Cancer | Melanoma | Late-stage trial | [http://www.clinicaltrials.gov/ct2/results?term=ipilimumab active PIII] | 0 |
Panitumumab | Amgen | Cancer | Colon cancer, other tumors | Awaiting regulatory decision | approved | 01269[http://www.drugbank.ca/drugs/DB01269 DB] |
Vatalanib (PTK-787) | Novartis, Schering | Cancer | Colon cancer | Late-stage trial | [http://www.clinicaltrials.gov/ct2/results?term=vatalanib active PIII] | 0 |
Provenge | Dendreon | Cancer | Prostate cancer | Late-stage trial | [http://www.clinicaltrials.gov/ct2/results?term=provenge active PIII] | 0 |
Telcyta (TLK286) | Telik | Cancer | Ovarian cancer | Late-stage trial | [http://www.clinicaltrials.gov/ct2/results?term=telcyta active PIII] | 0 |
Ticilimumab | Pfizer | Cancer | Melanoma | Mid-stage trial | [http://www.clinicaltrials.gov/ct2/results?term=Ticilimumab active PIII] | 0 |
Lapatinib | GlaxoSmithKline | Cancer | Breast cancer, bladder cancer | Late-stage trial | approved | 01259[http://www.drugbank.ca/drugs/DB01259 DB] |
Bavituximab | Perigrine Pharmaceuticals | Cancer | Solid tumer | ? | [http://www.clinicaltrials.gov/ct2/results?term=bavituximab PI PII] | 0 |
Cotara 131I-chTNT-1/B MAb | Perigrine Pharmaceuticals | Cancer | Glioblastoma | ? | [http://www.clinicaltrials.gov/ct2/results?term=cotara PI PII] | 0 |
Elesclomol | Synta | Cancer | Melanoma, metastatic | ? | [http://www.clinicaltrials.gov/ct2/results?term=elesclomol PII some suspended] | 0 |
Fostamatinib disodium (R935788) | Rigel | Autoimmune | Rheumatoid arthritis | ? | [http://www.clinicaltrials.gov/ct2/results?term=Fostamatinib PII] | 0 |
Palladia | Pfizer | Cancer | For Dogs | ? | 0 | |
Arzerra | Genmab, GlaxoSmithKline | Cancer | lymphocytic leukemia | Collab. initiated | [http://clinicaltrials.gov/ct2/results?term=Arzerra PII] | 0 |
Apremilast | Celgene | autoimmune | psoriatic arthritis | ? | [http://clinicaltrials.gov/ct2/results?term=apremilast PII] | 0 |
Aldesleukin (Proleukin) | Novartis | Cancer | Metastatic melanoma, metastatic kidney | ? | [http://www.clinicaltrials.gov/ct2/results?term=aldesleukin PI PII] | 0 |
Darusentan | Gilead Sciences | Cardiovascular | Hypertension | ? | [http://www.clinicaltrials.gov/ct2/results?term=darusentan PIII] | 0 |
Stimuvax (BLP25) | Oncothyreon, Merk Serono | Cancer | Carcinoma, Non-Small-Cell Lung; breast cancer | ? | [http://www.clinicaltrials.gov/ct2/results?term=stimuvax PII PII] | 0 |
Ocrelizumab | Genentech | Autoimmune | Rheumatoid arthritis | ? | [http://www.clinicaltrials.gov/ct2/results?term=ocrelizumab PII] | 0 |
Cixutumumab | ImClone | Cancer | Solid tumors | ? | [http://www.clinicaltrials.gov/ct2/results?term=cixutumumab PII] | 0 |
NVA237 | Novartis, Vectura | Pulmonary | chronic obstructive pulmonary disease | ? | [http://clinicaltrials.gov/ct2/results?term=NVA237 PII PIII] | 0 |
SEP-225289 | Sepracor | Neurological | Depressive disorder, major | ? | [http://www.clinicaltrials.gov/ct2/show/NCT00584974?term=sep-225289 PII] | 0 |
Lu AA24530 | Lundbeck | Neurological | Depressive disorder, major | ? | [http://www.clinicaltrials.gov/ct2/results?term=Lu+AA24530 PII] | 0 |
PRO-040201 | Tekmira Pharmaceuticals Corporation | Cardiovascular | Hypercholesterolemia | ? | [http://www.clinicaltrials.gov/ct2/results?term=tekmira PI] | 0 |
TB-402 | ThromboGenics, BioInvent | Cardiovascular | Blood thinner | ? | [http://www.clinicaltrials.gov/ct2/results?term=TB-402 PII] | 0 |
Saxagliptin (Onglyza, BMS-477118) | Bristol-Meyers Squibb | Metabolic | Diabetes, type 2 | ? | [http://www.clinicaltrials.gov/ct2/results?term=Saxagliptin PIII] | 0 |
This is the start of my user page. I want to contribute to articles pertaining to electricity generation and the politics and economics thereof. It would be great to see more work in this area from various wikipedia contributors.
class="prettytable"
!BPA transmission line uprgrades per 2005http://www.transmission.bpa.gov/PlanProj/Transmission_Projects/InfrastructureFactSheetMar2005.pdf!!Status!!Project Start!!Project Completion!!Miles!!kV!!Structure!!Capacity increase, MW!!Cost per mile!!Cost per added watt capacity!!Sub-station!!Total cost | |||||||||||
WA | |||||||||||
Franklin to Walla Walla | Pending | 2005 | 2005 | 18.5 | 115 | ? | ? | $302,703 | ? | ? | $5,600,000 |
Grand Coulee to Bell | Completed | ? | 2004 | 84 | 500 | steel latice | 1500 | $1,892,857 | $0.11 | ? | $159,000,000 |
Kangley to Echo Lake | Completed | 2000 | 2003 | 9 | 500 | ? | ? | $9,333,333 | ? | yes | $84,000,000 |
Raymond to Cosmopolis Rebuild | Completed | ? | 2004 | 18 | 115 | s.steel pole | ? | $622,222 | ? | ? | $11,200,000 |
Schultz to Wautona | Construction | ? | 2005? | 63 | 500 | ? | 600 | $2,761,905 | $0.29 | yes | $174,000,000 |
Hopkins Ridge Wind Intercnctn | Pending | 2005 | ? | 115 | ? | ? | 150 | ? | ? | ? | ? |
OR | |||||||||||
Albany to Eugene Rebuild | Completed | 2004 | 18 | 115 | ? | ? | ? | $411,111 | ? | ? | $7,400,000 |
Fort Yamhill Relocation | Pending | 2005 | ? | 115 | ? | ? | ? | ? | ? | ? | ? |
Combine Hills Wind Intercnctn | Pending | 2005 | ? | 5.8 | ? | wood | 63 | ? | ? | ? | ? |
Klondike III Wind Intercntctn | Pending | 2005 | 2006 | 10 | 230 | ? | 300 | ? | ? | ? | ? |
MT | |||||||||||
Libby to Troy Rebuild | Pending | 2005 | 17 | 115 | ? | ? | ? | ? | ? | ? | ? |
ID | |||||||||||
Anderson Ranch to Mountain Home Rebuild | 2004 | 18 | 115 | steel pole | ? | ? | ? | $194,444 | ? | ? | $3,500,000 |
Swan Valley to Goshen Rebuild | 2004 | 2006 | 25 | 161 | ? | wood | ? | $128,000 | ? | ? | $3,200,000 |
Forbes 2005
http://www.forbes.com/2005/08/02/pharmaceuticals-biotechnology-strokes-heart-disease-cx_mh_rl_cardiotear.html
class="prettytable"
!HEAD1!! HEAD2!! HEAD3!! HEAD4!!HEAD5 | ||||
R1C1 | R1C2 | R1C3 | R1C4 | R1C5 |
R2C1 | R2C2 | R2C3 | R2C4 | R2C5 |